Leslie Massey
Haemophilia is a rare, hereditary genetic condition that affects the body's ability to form blood clots, leading to prolonged bleeding after injuries, surgery, or other medical procedures. It is caused by a deficiency of clotting factors in the blood, specifically factor VIII in haemophilia A and factor IX in haemophilia B. In Australia, there are over 2,800 people with haemophilia, with varying degrees of severity, and it is more prevalent in males, affecting approximately 1-2 per 10,000. This prevalence rate is similar to that of other countries, with haemophilia A being the most common form worldwide. The condition imposes a significant burden on individuals, their families, and society, with high economic costs and negative impacts on employment and quality of life.
| Characteristics | Values |
|---|---|
| Prevalence of haemophilia in Australia | 2,800-3,300 people |
| Proportion of males with haemophilia in Australia | Nearly all |
| Mean annual prevalence of haemophilia A | 1-2 per 10,000 males |
| Proportion of people with haemophilia A in Australia | Approximately 1 in 6,000 males |
| Proportion of people with haemophilia B in Australia | Approximately 1 in 25,000-30,000 males |
| Prevalence of von Willebrand disease (VWD) in Australia | More than 2,600 people diagnosed, but many more undiagnosed |
| Impact of haemophilia on employment in Australia | 75% full-time employment rate for adults with severe haemophilia A compared to the general male population; 32% higher part-time employment rate; 2.3 times higher unemployment rate |
| Global impact of haemophilia on employment | Only one in five adults with moderate to severe haemophilia A and one in 20 people with inhibitors report no negative impact on employment |
| Countries with royal families affected by haemophilia | England, Prussia, Russia, Spain |
Explore related products
What You'll Learn
Haemophilia A prevalence in Australia
Haemophilia A (HA), also known as classical haemophilia, is the most common type of haemophilia in Australia. It is caused by a deficiency of the coagulation Factor VIII in the blood. The mean annual prevalence of HA in Australia is approximately 1-2 per 10,000 males, with more than 3,300 people diagnosed with varied degrees of severity. This is consistent with the international prevalence of haemophilia, which affects about 1 in 6,000-10,000 males.
HA is associated with a substantial economic burden, with high costs of treatment and care. The condition also imposes a significant burden on the health and quality of life of people with HA (PwHA), their families, and the community. PwHA often experience joint pain and joint disease, with up to 70% of adults suffering from joint problems. This can lead to difficulties in participating in sports and recreational activities, as well as missed school and work days due to bleeding-related events.
Prophylactic treatment is commonly used for people with moderate (25.1%) and severe (82.2%) HA. However, within the severe HA group, 16.1% have inhibitors for Factor VIII, which leads to worse morbidity, mortality, and quality of life. These individuals may require specialised treatments to help their blood clot normally and effectively manage their condition.
In Australia, the rate of full-time employment for adults with severe HA is lower than that of the general male population. The part-time employment rate is 32% higher, and the unemployment rate is 2.3 times higher. Self-employment is more common among PwHA, especially those with inhibitors. This may be due to the flexibility and accommodation that self-employment can offer to manage the challenges associated with HA.
While the social and economic impacts of HA in Australia are significant, with proper treatment and management, individuals with haemophilia can lead effective and fulfilling lives.
Australia's Ultimate Foodie Destinations
You may want to see also
Explore related products
Haemophilia B prevalence in Australia
Haemophilia is a rare hereditary genetic bleeding disorder that occurs in about 1 in 6,000-10,000 males internationally. Haemophilia B, also known as Christmas Disease, occurs when there is a lack of clotting factor IX in the blood. While Haemophilia A is the most common type, with more than 3,300 cases of varying severity diagnosed in Australia, Haemophilia B also has a notable presence in the country.
The annual prevalence of Haemophilia B in Australia is approximately 1-2 per 10,000 males, similar to the global prevalence of Haemophilia. This translates to an incidence of 11.5 per 100,000 for Haemophilia B in the country. While this number may seem small, the impact of the disorder is significant. Those with Haemophilia B experience internal bleeding, including in joints, muscles, and organs, which can occur spontaneously or after an injury or surgery. Over time, repeated bleeding into joints and muscles can lead to arthritis, chronic pain, and disability.
The economic burden of Haemophilia B in Australia is substantial. While specific cost estimates for Haemophilia B are not available, studies have shown that the overall economic impact of haemophilia in Australia is high. The specialised treatment required to manage the disorder effectively contributes to the financial strain. Prophylactic treatment is often necessary, and the condition can lead to missed work and school, further emphasising the economic toll it takes on individuals, their families, and the community.
The impact of Haemophilia B extends beyond physical health and economic concerns. The disorder can affect an individual's ability to participate in sports and recreational activities, impacting their quality of life. Additionally, the perception of self and the burden on the family must be considered. While studies on the social implications of Haemophilia in Australia are limited, it is clear that the disorder presents challenges in various aspects of life.
In summary, while the prevalence of Haemophilia B in Australia is low, the impact of the disorder is far-reaching. The condition affects not only the physical health of individuals but also their economic stability, quality of life, and overall well-being. As such, it is essential to recognise the significance of Haemophilia B in Australia and provide support and resources to those affected by the disorder.
Grow Your Own Roses: Cuttings for Australian Climates
You may want to see also
Explore related products
Haemophilia's economic burden in Australia
Haemophilia A (HA) is an X-linked congenital bleeding disorder caused by a deficiency of the coagulation Factor VIII (FVIII). HA accounts for approximately 80% of all haemophilia cases in Australia. It is a rare disease, with a mean annual prevalence of 1-2 per 10,000 males.
The economic burden of HA in Australia is substantial, despite the condition affecting a relatively small number of people. The costs of HA are high, and these costs are borne by patients, their families, and the wider community. The impact of HA on individuals' lives is significant, with many experiencing joint pain and joint disease, and up to 70% of adults with HA experiencing joint problems. This can lead to missing school or work due to bleeding-related events, with a subsequent loss of income. In addition, the need for specialised treatment and care can result in further financial strain.
The impact of HA on caregivers and families is also considerable. In a European study, two-thirds of caregivers of children with severe HA reported that the condition affected family life, and 27% reported an economic impact. Caregivers of children with HA with inhibitors face an even larger burden, with a higher number of days missed from work and a greater impact on full-time employment.
In Australia, the government provides financial support to people who provide daily care to someone with a severe disability or medical condition. This may help to alleviate some of the economic burdens associated with HA. However, the costs of HA are still significant and vary greatly between countries.
Overall, HA imposes a notable economic burden on those affected and their families in Australia, with potential flow-on effects on the wider community. The condition's rarity means that those with HA may face unique challenges and costs when accessing treatment and support.
Muslim Population in Australia: How Many?
You may want to see also
Explore related products
Haemophilia's social impact in Australia
Haemophilia A (HA) is a congenital bleeding disorder caused by a deficiency of the coagulation Factor VIII (FVIII). It is the most common type of haemophilia, with an annual prevalence of approximately 1-2 per 10,000 males in Australia. This means that there are more than 3,300 people in Australia diagnosed with varied degrees of severity.
HA is associated with a substantial economic burden, with high costs for treatment and care. The economic burden of HA falls not only on those with the condition but also on their families and the community at large. HA is also associated with poor physical health, and people with HA often miss school or work due to bleeding-related events. This results in a reduced quality of life for people with HA and their caregivers compared to healthy individuals. Up to 70% of adults with HA experience joint problems, and repeated bleeding into joints and muscles can cause arthritis, chronic pain, and disability.
The impact of HA on quality of life is most noticeable for those with severe cases of the disorder or those with inhibitors to FVIII. The development of inhibitors, or antibodies to FVIII, can render treatment ineffective and lead to worse morbidity, mortality, and quality of life. Globally, only one in five adults with moderate to severe HA, and one in 20 people with inhibitors, say that haemophilia has had no negative impact on their employment. In Australia, the rate of full-time employment for adults with severe HA is 75% of that for the general male population, while the unemployment rate is 2.3 times higher.
While there is limited data on the social impacts of HA in Australia, it is clear that the disorder imposes a significant burden on those affected and their communities. With appropriate treatment, however, HA can be effectively managed.
IT Jobs: Why Australia is a Top Destination
You may want to see also
Haemophilia treatment in Australia
Haemophilia is a rare bleeding disorder that affects approximately 1-2 per 10,000 males in Australia, with over 3,300 people currently diagnosed with varying degrees of severity. The most common type is Haemophilia A (classical haemophilia), which occurs when there is a deficiency of clotting Factor VIII in the blood. This can lead to internal bleeding in any part of the body, including joints, muscles, and organs, especially after an injury or surgery. Repeated bleeding into joints and muscles can cause arthritis, chronic pain, and disability over time.
Haemophilia Foundation Australia provides support and resources for those affected by the condition, and there are treatment centres dedicated to helping those with bleeding disorders. Treatment and care for haemophilia involve a team of specialist health professionals, and Australia has guidelines in place for the management and diagnosis of the condition.
Prophylactic treatment is a common approach, with one-quarter of people with moderate haemophilia and 82.2% of those with severe haemophilia receiving this type of treatment. However, even with treatment, haemophilia can impose a significant burden on those affected and their families. It is associated with poor physical health, leading to missed school and work due to bleeding-related events. It also has economic impacts, with higher costs reported in Australia compared to some other countries.
The condition can also affect employment prospects, with higher rates of unemployment and early retirement due to long-term disability observed in Australia. Additionally, there are social impacts associated with haemophilia, including reduced participation in sports and recreational activities, which can affect quality of life. Overall, while haemophilia can be effectively managed with appropriate treatment, it presents a substantial challenge for those affected in Australia and beyond.
Travel Bans: Australia's Government Advice Against Traveling
You may want to see also
Frequently asked questions
In Australia, there are more than 2,800 people with haemophilia, nearly all male. Approximately one in 6,000 males has haemophilia A, and one in 25,000-30,000 males has haemophilia B.
Haemophilia is a rare condition worldwide. However, the exact prevalence varies between countries.
Haemophilia A, or classical haemophilia, is the most common type, affecting approximately 1-2 per 10,000 males annually.
Globally, haemophilia A is the most common form, followed by haemophilia B, which is less prevalent.
In Australia, haemophilia impacts employment rates, with a higher rate of unemployment and self-employment among those with severe haemophilia. Similar impacts on employment have been observed in other countries, with reduced work participation rates reported.
